These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27868138)

  • 1. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.
    Schneiderbauer R; Schneiderbauer M; Wick W; Enk AH; Haenssle HA; Hassel JC
    Acta Derm Venereol; 2017 Mar; 97(3):395-396. PubMed ID: 27868138
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
    Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
    Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
    Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma.
    Thoreau B; Gouaillier-Vulcain F; Machet L; Mateus C; Robert C; Ferreira-Maldent N; Maillot F; Lioger B
    Acta Derm Venereol; 2017 Mar; 97(3):408-409. PubMed ID: 27377178
    [No Abstract]   [Full Text] [Related]  

  • 6. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 7. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
    Gaudy-Marqueste C; Monestier S; Franques J; Cantais E; Richard MA; Grob JJ
    J Immunother; 2013 Jan; 36(1):77-8. PubMed ID: 23211620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
    Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
    Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
    Beniwal-Patel P; Matkowskyj K; Caldera F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
    Wilgenhof S; Neyns B
    Ann Oncol; 2011 Apr; 22(4):991-993. PubMed ID: 21357649
    [No Abstract]   [Full Text] [Related]  

  • 12. PD-1 inhibitor becomes "breakthrough therapy".
    Cancer Discov; 2013 Jul; 3(7):OF14. PubMed ID: 23847357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient.
    Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P
    Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
    Deltombe C; Garandeau C; Renaudin K; Hourmant M
    Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
    [No Abstract]   [Full Text] [Related]  

  • 15. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare heart risk found with checkpoint inhibitors.
    Printz C
    Cancer; 2017 May; 123(9):1483-1484. PubMed ID: 28430361
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
    Johnson DB; Wallender EK; Cohen DN; Likhari SS; Zwerner JP; Powers JG; Shinn L; Kelley MC; Joseph RW; Sosman JA
    Cancer Immunol Res; 2013 Dec; 1(6):373-7. PubMed ID: 24490176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
    Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
    Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab success in untreated metastatic melanoma.
    Wilkinson E
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.